Suzhou Cure Genetics Biotechnology Ltd. (“Cure Genetics Ltd”) was established in 2016, located in Suzhou Biomedical Industrial Park. It is a gene diagnosis and treatment company co-founded by the co-inventors of CRISPR gene-editing technology. Cure Genetics focuses on the original application and development of CRISPR technology in new medicines, and is committed to solving the clinical needs of incurable tumors and complex genetic diseases, establishing a gene-editing technology platform with independent intellectual property rights and creating a global benchmark in the field of gene therapy.
In 2020, JITRI, Suzhou Industrial Technology Research Institute, and Suzhou Biomedical Industrial Park jointly provided R&D funds to support Cure Genetics’ development of the unique screening platform for global gene therapy’s pain points: low specificity of carrier tissue and insufficient production capacity, aiming to develop a unique screening platform and process. This project focuses on developing gene therapy products for congenital spinal muscular atrophy (SMA). With the support of the Cure Genetics’ virus serum screening system, this project benchmarks Novartis’ Zolgensma's product to quickly search for neurological tissues with high specificity, low immunogenicity and strong infection efficiency for the nervous system tissues. It has increased the production capacity of viral vectors and achieved substantial cost reduction, which laid the foundation for the product to become a gene therapy drug in the field of SMA disease. At present, the company will cooperate with Boehringer Ingelheim (BI), the world's largest family multinational pharmaceutical company in the Adeno-Associated Virus AAV screening production process. The cooperation between the two parties is mainly based on Cure Genetics’ exclusive AAV serotype screening system and the world’s top AAV large-scale production capacity, with the AAV serotype that specifically infects liver cells as the target, to jointly build a universal gene therapy technology platform. At the same time, Cure Genetics will provide BI with continuous GMP-level AAV virus production to support BI's global gene therapy layout.